In the past week, GYRE stock has gone down by -16.18%, with a monthly decline of -33.45% and a quarterly plunge of -41.20%. The volatility ratio for the week is 11.83%, and the volatility levels for the last 30 days are 12.14% for Gyre Therapeutics Inc The simple moving average for the past 20 days is -24.66% for GYRE’s stock, with a -36.48% simple moving average for the past 200 days.
Is It Worth Investing in Gyre Therapeutics Inc (NASDAQ: GYRE) Right Now?
Gyre Therapeutics Inc (NASDAQ: GYRE) has a higher price-to-earnings ratio of 64.77x compared to its average ratio. GYRE has 36-month beta value of 1.91. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GYRE is 16.27M, and currently, short sellers hold a 9.38% ratio of that float. The average trading volume of GYRE on April 01, 2025 was 121.65K shares.
GYRE) stock’s latest price update
Gyre Therapeutics Inc (NASDAQ: GYRE) has experienced a decline in its stock price by -15.26 compared to its previous closing price of 9.11. However, the company has seen a fall of -16.18% in its stock price over the last five trading days. globenewswire.com reported 2025-03-31 that SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People’s Republic of China (“PRC”) has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary complications. The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP).
Analysts’ Opinion of GYRE
Stephens, on the other hand, stated in their research note that they expect to see GYRE reach a price target of $19, previously predicting the price at $18. The rating they have provided for GYRE stocks is “Overweight” according to the report published on April 29th, 2021.
Piper Sandler gave a rating of “Overweight” to GYRE, setting the target price at $15 in the report published on February 10th of the previous year.
GYRE Trading at -30.28% from the 50-Day Moving Average
After a stumble in the market that brought GYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.37% of loss for the given period.
Volatility was left at 12.14%, however, over the last 30 days, the volatility rate increased by 11.83%, as shares sank -32.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.52% lower at present.
During the last 5 trading sessions, GYRE fell by -16.18%, which changed the moving average for the period of 200-days by -28.45% in comparison to the 20-day moving average, which settled at $10.25. In addition, Gyre Therapeutics Inc saw -36.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GYRE starting from Ma Songjiang, who sale 174 shares at the price of $10.00 back on Mar 21 ’25. After this action, Ma Songjiang now owns 2,824,844 shares of Gyre Therapeutics Inc, valued at $1,740 using the latest closing price.
Ma Songjiang, the President of Gyre Therapeutics Inc, sale 2,000 shares at $10.13 during a trade that took place back on Mar 19 ’25, which means that Ma Songjiang is holding 2,827,018 shares at $20,260 based on the most recent closing price.
Stock Fundamentals for GYRE
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.96 for the gross margin
The net margin for Gyre Therapeutics Inc stands at 0.27. The total capital return value is set at 0.15.
Based on Gyre Therapeutics Inc (GYRE), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -2.28.
Currently, EBITDA for the company is 16.16 million with net debt to EBITDA at -0.59. When we switch over and look at the enterprise to sales, we see a ratio of 6.21. The receivables turnover for the company is 3.63for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.32.
Conclusion
To put it simply, Gyre Therapeutics Inc (GYRE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
